Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | FDFT1 | P37268 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 2/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.34 |
| ▸ | ATM | Q13315 | 1/20 | 0.34 |
| ▸ | KRAS | P01116 | 2/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4128321 | 1.00 | ALDH1A1 (0.35) | ALDH1A1MAPTBCHEFDFT1MEN1 | |
| SCHEMBL13775240 | 0.86 | FDFT1 (0.39) | ALDH1A1MAPTFDFT1NFE2L2L3MBTL1 | |
| SCHEMBL13775256 | 0.83 | ALDH1A1 (0.39) | ALDH1A1MAPTFDFT1MEN1KMT2A | |
| SCHEMBL4127985 | 0.82 | RAB9A (0.36) | ALDH1A1BCHEMEN1KMT2AKRAS | |
| SCHEMBL4127982 | 0.82 | RAB9A (0.36) | ALDH1A1BCHEMEN1KMT2AKRAS | |
| SCHEMBL13775454 | 0.82 | KDM4E (0.34) | ALDH1A1MAPTBCHEFDFT1KRAS | |
| SCHEMBL13775457 | 0.80 | NR1H4 (0.36) | ALDH1A1NFE2L2KDM4ENR1H4 | |
| SCHEMBL4123855 | 0.80 | FDFT1 (0.37) | ALDH1A1MAPTFDFT1NFE2L2L3MBTL1 | |
| SCHEMBL4123861 | 0.80 | FDFT1 (0.37) | ALDH1A1MAPTFDFT1NFE2L2L3MBTL1 | |
| SCHEMBL13775445 | 0.80 | GAA (0.40) | ALDH1A1MAPTFDFT1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-07-16 | — | — | US | disclosed |
| EP-1939205-A1 | TRICYCLIC COMPOUND | Daiichi Sankyo Company, Limited (JP) | 2008-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090181942-A1 | TRICYCLIC COMPOUNDS | FDFT1, COASY, HMGCR | ALDH1A1 1587/4885MAPT 4428/4885BCHE 201/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.